Luke Forde
Luke Forde has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Debananda Gogoi
Microbial Biotechnology and Protein Research Laboratory, Department of Molecular Biology and Biotechnology, School of Sciences, Tezpur University, Tezpur, 784028, Assam, India
6 shared publications - Emer Patricia Reeves
Royal College of Surgeons in Ireland Dublin, Ireland
6 shared publications - Rory Baird
Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, RCSI University of Medicine and Health Sciences , Dublin
5 shared publications - Mengxin Niu
Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, RCSI University of Medicine and Health Sciences , Dublin
4 shared publications - Sara Waqas Ahmed
Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, RCSI University of Medicine and Health Sciences , Dublin
4 shared publications Emmet E. McGrath
3 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Purinergic receptor remodelling in circulating and airway cells of patients with progressive fibrotic lung disease
- 23 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPurinergic receptor remodelling in circulating and airway cells of patients with progressive fibrotic lung disease
- Open Access
- 1 January 2026
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 18 (1) , 104-119
Inhibition of Pseudomonas aeruginosa Biofilm Formation by Peptidyl-Arginine Deiminases 2 and 4
Introduction: Pseudomonas aeruginosa is a significant pathogen associated with acute and chronic infections, particularly in immunocompromised individuals. Its capacity for biofilm formation, combined with antibiotic resistance, plays a critical role in the persistence of these infections. Peptidyl-arginine deiminases (PADs), including PAD2 and PAD4 isoforms, are involved in neutrophil phagocytic killing of P. aeruginosa. This study aimed to investigate the impact of PAD enzymes on biofilm development and virulence factor production in P. aeruginosa, with focus on the multidrug resistant strain, PGO2330. Methods: Biofilm formation was assessed using crystal violet assays and confocal scanning laser microscopy. Quorum sensing (QS) gene expression and QS-related virulence factor production were quantified using qPCR and virulence factor assays. Results: Exposure to 20 nm of PAD2 or PAD4 reduced PGO2330 surface attachment (p < 0.0001) and biofilm formation to 67.9 ± 5.6% (p < 0.0001) and 68.2 ± 4.2% (p = 0.0004), respectively. Moreover, rPAD2 and rPAD4 citrullinated multiple protein substrates of P. aeruginosa, yet citrullination activity was not required by rPADs to reduce P. aeruginosa biofilm formation. PGO2330 exposed to PAD2 and PAD4 showed reduced lasR, lasI, rhlR, rhlI, and mvfR gene expression and reduced levels of extracellular DNA, rhamnolipids, pyocyanin, and protease activity. Conclusion: These results demonstrate that PADs inhibit P. aeruginosa biofilm formation and decrease the production of QS-related virulence factors, highlighting their potential as novel antimicrobials and supporting further research into the development of PAD-based therapeutics.
- 1 January 2026
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 18 (1) , 104-119
Open AccessInhibition of Pseudomonas aeruginosa Biofilm Formation by Peptidyl-Arginine Deiminases 2 and 4
Introduction: Pseudomonas aeruginosa is a significant pathogen associated with acute and chronic infections, particularly in immunocompromised individuals. Its capacity for biofilm formation, combined with antibiotic resistance, plays a critical role in the persistence of these infections. Peptidyl-arginine deiminases (PADs), including PAD2 and PAD4 isoforms, are involved in neutrophil phagocytic killing of P. aeruginosa. This study aimed to investigate the impact of PAD enzymes on biofilm development and virulence factor production in P. aeruginosa, with focus on the multidrug resistant strain, PGO2330. Methods: Biofilm formation was assessed using crystal violet assays and confocal scanning laser microscopy. Quorum sensing (QS) gene expression and QS-related virulence factor production were quantified using qPCR and virulence factor assays. Results: Exposure to 20 nm of PAD2 or PAD4 reduced PGO2330 surface attachment (p < 0.0001) and biofilm formation to 67.9 ± 5.6% (p < 0.0001) and 68.2 ± 4.2% (p = 0.0004), respectively. Moreover, rPAD2 and rPAD4 citrullinated multiple protein substrates of P. aeruginosa, yet citrullination activity was not required by rPADs to reduce P. aeruginosa biofilm formation. PGO2330 exposed to PAD2 and PAD4 showed reduced lasR, lasI, rhlR, rhlI, and mvfR gene expression and reduced levels of extracellular DNA, rhamnolipids, pyocyanin, and protease activity. Conclusion: These results demonstrate that PADs inhibit P. aeruginosa biofilm formation and decrease the production of QS-related virulence factors, highlighting their potential as novel antimicrobials and supporting further research into the development of PAD-based therapeutics.
- 23 September 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (3) , 403-406
CFTR modulator therapy impacts neutrophil CD39 expression in cystic fibrosis
- 23 September 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (3) , 403-406
CFTR modulator therapy impacts neutrophil CD39 expression in cystic fibrosis
- Open Access
- 1 January 2025
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 17 (1) , 468-486
A Review of Proteases and Antiproteases for Immune Regulation and Potential Therapeutic Application in Pulmonary Fibrosis
Background: Interstitial lung diseases (ILDs) or diffuse parenchymal lung diseases are general terms for a group of over 200 conditions that result from the destruction of cells neighbouring the alveoli, leading to extensive inflammation and fibrosis of the lungs. Although different types of ILD have distinct pathophysiology, clinical display, and advancement, many forms drive irreversible pulmonary fibrosis (PF), leading to progressive functional impairment, respiratory failure, and mortality. Summary: Key components of innate immunity include proteases and their cognate inhibitors, which are involved in respiratory homoeostasis. Alterations to the protease-antiprotease balance can lead to pulmonary disease and fibrotic scarring of the lungs, and over the past two decades, there has been a surge in research exploring their effect on the pathogenesis of ILDs. We have evaluated relevant studies regarding these enzymes in the context of lung fibrosis and have discussed prospects for developing novel treatments. This review will place greater emphasis on the overall effect of proteases and antiproteases to the development of PF, as studied using both in vivo and in vitro models. Key Message: Considering the limited therapeutic interventions, continued research on proteolytic enzymes and their inhibitors is required for the development of novel effective treatments for PF.
- 1 January 2025
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 17 (1) , 468-486
Open AccessA Review of Proteases and Antiproteases for Immune Regulation and Potential Therapeutic Application in Pulmonary Fibrosis
Background: Interstitial lung diseases (ILDs) or diffuse parenchymal lung diseases are general terms for a group of over 200 conditions that result from the destruction of cells neighbouring the alveoli, leading to extensive inflammation and fibrosis of the lungs. Although different types of ILD have distinct pathophysiology, clinical display, and advancement, many forms drive irreversible pulmonary fibrosis (PF), leading to progressive functional impairment, respiratory failure, and mortality. Summary: Key components of innate immunity include proteases and their cognate inhibitors, which are involved in respiratory homoeostasis. Alterations to the protease-antiprotease balance can lead to pulmonary disease and fibrotic scarring of the lungs, and over the past two decades, there has been a surge in research exploring their effect on the pathogenesis of ILDs. We have evaluated relevant studies regarding these enzymes in the context of lung fibrosis and have discussed prospects for developing novel treatments. This review will place greater emphasis on the overall effect of proteases and antiproteases to the development of PF, as studied using both in vivo and in vitro models. Key Message: Considering the limited therapeutic interventions, continued research on proteolytic enzymes and their inhibitors is required for the development of novel effective treatments for PF.
- Open Access
- 11 December 2024
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 17 (1) , 44-55
Does Adenosine Triphosphate via Purinergic Receptor Signalling Fuel Pulmonary Fibrosis?
Background: Interstitial lung diseases (ILD) are poorly understood disorders characterised by diffuse damage to the lung parenchyma, with inflammation and fibrosis. Some manifest a progressive fibrotic phenotype with high fatality and limited treatment options, such as idiopathic pulmonary fibrosis. Summary: The degree to which inflammation plays a role in fibrosis progression is unknown. However, wound healing and fibrosis are intricate processes influenced by various inflammatory factors. Extracellular nucleosides and nucleotides, including adenosine triphosphate, activate pro-inflammatory responses to innate immunity and are widely implicated in tissue fibrosis across different organs. The pro-inflammatory effects of extracellular nucleotides occur via P1 and P2 purinergic receptors, expressed across the lung and immune system, and have been implicated in various pulmonary diseases including pulmonary fibrosis. This review amalgamates available data on the complex role of P1 and P2 purinergic receptor signalling in pulmonary fibrosis and discusses perspectives for novel treatments. Key Messages: Purinergic signalling plays a complex and pivotal role in pulmonary fibrosis, warranting further study. The intricate interplay between P1 and P2 receptor pathways necessitates a comprehensive approach to understand their collective impact. While evidence from preclinical models is promising, human studies are essential for further understanding of pulmonary fibrosis. Advances in receptor-specific agonists and antagonists provide novel avenues for research and may ultimately lead to new therapies for patients.
- 11 December 2024
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 17 (1) , 44-55
Open AccessDoes Adenosine Triphosphate via Purinergic Receptor Signalling Fuel Pulmonary Fibrosis?
Background: Interstitial lung diseases (ILD) are poorly understood disorders characterised by diffuse damage to the lung parenchyma, with inflammation and fibrosis. Some manifest a progressive fibrotic phenotype with high fatality and limited treatment options, such as idiopathic pulmonary fibrosis. Summary: The degree to which inflammation plays a role in fibrosis progression is unknown. However, wound healing and fibrosis are intricate processes influenced by various inflammatory factors. Extracellular nucleosides and nucleotides, including adenosine triphosphate, activate pro-inflammatory responses to innate immunity and are widely implicated in tissue fibrosis across different organs. The pro-inflammatory effects of extracellular nucleotides occur via P1 and P2 purinergic receptors, expressed across the lung and immune system, and have been implicated in various pulmonary diseases including pulmonary fibrosis. This review amalgamates available data on the complex role of P1 and P2 purinergic receptor signalling in pulmonary fibrosis and discusses perspectives for novel treatments. Key Messages: Purinergic signalling plays a complex and pivotal role in pulmonary fibrosis, warranting further study. The intricate interplay between P1 and P2 receptor pathways necessitates a comprehensive approach to understand their collective impact. While evidence from preclinical models is promising, human studies are essential for further understanding of pulmonary fibrosis. Advances in receptor-specific agonists and antagonists provide novel avenues for research and may ultimately lead to new therapies for patients.
- 1 June 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 70 (6) , 524-527
Augmentation Therapy Decreases Platelet-Neutrophil Aggregates in Alpha-1 Antitrypsin Deficiency
- 1 June 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 70 (6) , 524-527
Augmentation Therapy Decreases Platelet-Neutrophil Aggregates in Alpha-1 Antitrypsin Deficiency
- 31 May 2018
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 188 (1) , 135-139
Coeliac screening in a high-risk population: paediatric type 1 diabetes—a review of current guidelines and practice
Coeliac disease (CD) is more common in those with type 1 diabetes mellitus (T1DM) and may be asymptomatic despite the presence of intestinal histological changes. Optimal screening practice guidelines differ internationally. We undertook a retrospective audit to determine the efficacy of current screening practice for CD in T1DM in our centre.
- 31 May 2018
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 188 (1) , 135-139
Coeliac screening in a high-risk population: paediatric type 1 diabetes—a review of current guidelines and practice
Coeliac disease (CD) is more common in those with type 1 diabetes mellitus (T1DM) and may be asymptomatic despite the presence of intestinal histological changes. Optimal screening practice guidelines differ internationally. We undertook a retrospective audit to determine the efficacy of current screening practice for CD in T1DM in our centre.